We would love to hear your thoughts about our site and services, please take our survey here.
Research Note just out from Logica2me Investments.
Research Note: ANGLE plc Breakthrough in DNA Molecular Analysis of Cancer Patient Blood Samples
Summary:
ANGLE plc has achieved groundbreaking clinical results through the combined analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) using its Parsortix system. The analysis, conducted on forty-seven patient samples across breast, lung, prostate, and ovarian cancers, revealed actionable DNA variants in CTCs not present in ctDNA, offering a unique insight into cancer progression.
Key Findings:
Clinical Significance: The analysis demonstrated the ability to identify actionable DNA variants in CTCs, not present in ctDNA, in 70% of breast cancer samples, 70% of lung cancer samples, and 60% of ovarian cancer samples. These variants included targets for FDA-approved cancer drugs.
Therapeutic Implications: Molecular profiling of CTC-DNA alongside ctDNA may revolutionize cancer treatment by informing treatment decisions, monitoring response to therapy, highlighting drug resistance, and signaling disease progression.
Product and Pharma Services Growth: ANGLE anticipates an increase in product and pharma services sales as a result of these breakthrough results. The company has developed a sample-to-answer molecular solution for real-time Next Generation Sequencing (NGS) DNA analysis.
Unique Insight: The Parsortix system's ability to analyze CTCs and ctDNA from the same blood sample provides a new and unique insight into cancer clonal evolution. This approach could support routine repeat blood tests for tracking cancer progression.
Future Prospects: ANGLE plans to leverage these clinical results to offer sample-to-answer DNA molecular solutions to pharma services customers. The company aims to work with key opinion leaders and clinicians to expedite clinical adoption and conduct further studies.
Potential Extensions: Beyond DNA analysis, the CTC samples offer the potential for extended analysis into RNA, protein, and morphological aspects, making intact living cancer cells (CTCs) a valuable sample for personalized care.
ANGLE's breakthrough represents a critical step in demonstrating the clinical value of NGS molecular analysis on living cancer cells harvested from patient blood samples, potentially transforming cancer diagnosis and treatment.
Verdict: STRONG BUY
Price target 156p
Research Note just out from Logica2me Investments.
Research Note: ANGLE plc Breakthrough in DNA Molecular Analysis of Cancer Patient Blood Samples
Summary:
ANGLE plc has achieved groundbreaking clinical results through the combined analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) using its Parsortix system. The analysis, conducted on forty-seven patient samples across breast, lung, prostate, and ovarian cancers, revealed actionable DNA variants in CTCs not present in ctDNA, offering a unique insight into cancer progression.
Key Findings:
Clinical Significance: The analysis demonstrated the ability to identify actionable DNA variants in CTCs, not present in ctDNA, in 70% of breast cancer samples, 70% of lung cancer samples, and 60% of ovarian cancer samples. These variants included targets for FDA-approved cancer drugs.
Therapeutic Implications: Molecular profiling of CTC-DNA alongside ctDNA may revolutionize cancer treatment by informing treatment decisions, monitoring response to therapy, highlighting drug resistance, and signaling disease progression.
Product and Pharma Services Growth: ANGLE anticipates an increase in product and pharma services sales as a result of these breakthrough results. The company has developed a sample-to-answer molecular solution for real-time Next Generation Sequencing (NGS) DNA analysis.
Unique Insight: The Parsortix system's ability to analyze CTCs and ctDNA from the same blood sample provides a new and unique insight into cancer clonal evolution. This approach could support routine repeat blood tests for tracking cancer progression.
Future Prospects: ANGLE plans to leverage these clinical results to offer sample-to-answer DNA molecular solutions to pharma services customers. The company aims to work with key opinion leaders and clinicians to expedite clinical adoption and conduct further studies.
Potential Extensions: Beyond DNA analysis, the CTC samples offer the potential for extended analysis into RNA, protein, and morphological aspects, making intact living cancer cells (CTCs) a valuable sample for personalized care.
ANGLE's breakthrough represents a critical step in demonstrating the clinical value of NGS molecular analysis on living cancer cells harvested from patient blood samples, potentially transforming cancer diagnosis and treatment.
Verdict: STRONG BUY
Price target 156p
Unique insights gained from breakthrough results in molecular analysis of cancer patient blood samples. Molecular profiling of CTC-DNA, from CTCs enriched by Parsortix® technology, alongside ctDNA from the same blood sample has the potential to revolutionize cancer treatment
You'd be hard pressed to find such a strong day over the past 6 months.
80p placing from July
No cash needed
20M volume
130p Broker Target
Jan 11th - Proactive Presentation
Zak Mir - break 23 and goes to 35 released 60mins ago
WOW.....
...We genuinely believe that today's announcement may turn out to be an absolutely ground breaking change in the way that cancer is perceived...
Volume just cracked 17M before midday. You'd be hard pressed to find such a strong day over the past 6 months.
80p placing from July
No cash needed
17M volume
130p Broker Target
Jan 11th - Proactive Presnetation
Zak Mir - break 23 and goes to 35 released 10 mins ago
Big Pharma can not ignore this...
Amazing results. Shows power of Parsortix.
"Actionable variants identified in our patient cohort in the CTCs that were not present in the ctDNA included variants targeted by widely used drugs from many large pharma companies, for example:
-- PIK3CA (E545K): Alpelisib (Piqray(R) ) marketed by Novartis
-- EGFR (T790M): Tagrisso (Osimertinib(R) ) marketed by Astra Zeneca
-- ESR1 (K303R): Elacestrant (Oserdu(R) ) marketed by Menarini
-- MTOR (T1977K): Everolimus (Afinitor(R) ) marketed by Novartis
-- ERBB2 (R678Q): Trastuzumab, Pertuzumab, Neratinib, Afatinib marketed respectively by Astra Zeneca, Roche Genentech, Puma Biotechnology, and Boehringer Ingelheim
Big Pharma can not ignore this...
Amazing results. Shows power of Parsortix.
"Actionable variants identified in our patient cohort in the CTCs that were not present in the ctDNA included variants targeted by widely used drugs from many large pharma companies, for example:
-- PIK3CA (E545K): Alpelisib (Piqray(R) ) marketed by Novartis
-- EGFR (T790M): Tagrisso (Osimertinib(R) ) marketed by Astra Zeneca
-- ESR1 (K303R): Elacestrant (Oserdu(R) ) marketed by Menarini
-- MTOR (T1977K): Everolimus (Afinitor(R) ) marketed by Novartis
-- ERBB2 (R678Q): Trastuzumab, Pertuzumab, Neratinib, Afatinib marketed respectively by Astra Zeneca, Roche Genentech, Puma Biotechnology, and Boehringer Ingelheim
Big Pharma can not ignore this...
Amazing results. Shows power of Parsortix.
"Actionable variants identified in our patient cohort in the CTCs that were not present in the ctDNA included variants targeted by widely used drugs from many large pharma companies, for example:
-- PIK3CA (E545K): Alpelisib (Piqray(R) ) marketed by Novartis
-- EGFR (T790M): Tagrisso (Osimertinib(R) ) marketed by Astra Zeneca
-- ESR1 (K303R): Elacestrant (Oserdu(R) ) marketed by Menarini
-- MTOR (T1977K): Everolimus (Afinitor(R) ) marketed by Novartis
-- ERBB2 (R678Q): Trastuzumab, Pertuzumab, Neratinib, Afatinib marketed respectively by Astra Zeneca, Roche Genentech, Puma Biotechnology, and Boehringer Ingelheim